Lilly acquires new injectable medicine manufacturing facility from Nexus Pharmaceuticals
Upon completion, this acquisition will expand Lilly's growing U.S. capacity to produce the latest life-changing medicines
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Apr 24
Upon completion, this acquisition will expand Lilly's growing U.S. capacity to produce the latest life-changing medicines
19 Apr 24
Collaboration Leverages Variant Bio's Cutting-edge Genomic Discovery Platform And Evotec's Integrated End-to-end R&d Platform And Disease Area Expertise…
18 Apr 24
Clearmind will get exclusive global rights to develop, research, manufacture, and market products derived from psychedelic compounds, which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
18 Apr 24
Under the collaboration, A*STAR will offer its iPSC banks, specialised monoclonal antibody assets, process scaling, and analytics skills…
17 Apr 24
Manufactured by Alvotech, Selarsdi is the second biosimilar approved under the strategic partnership between Alvotech and Teva, for…
17 Apr 24
Medincell and AbbVie will co-develop up to six LAI therapeutic products whereas AbbVie will provide funding, manage the…
17 Apr 24
Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development
15 Apr 24
In the Phase 3 study, Columvi plus chemotherapy showed a statistically significant improvement in overall survival (OS), progression-free…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Apr 24
The German drug maker will also get an exclusive global license to develop, manufacture and market the resulting…
04 Apr 24
The approval for Zevtera was based on the clinical efficacy and safety data from the Phase 3 ERADICATE…